Respiratory medicine
-
Respiratory medicine · Jun 2013
Randomized Controlled Trial Multicenter Study Comparative StudySafety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
To determine the safety and efficacy of BEA2180, an anticholinergic agent in patients with chronic obstructive pulmonary disease (COPD). ⋯ All study doses of BEA2180 improved lung function, reduced symptoms and exacerbations, and improved health status in COPD; all treatments were well tolerated. Clinical trial identifier: NCT00528996.